Business Context and Reporting Period
Company: Advanced Biomed Inc. (ADVB)
Filing Type: Form 8-K (Current Report)
Date of Report: March 12, 2026
Reporting Period: The filing addresses events occurring between July 18, 2025, and March 12, 2026, specifically regarding the company's listing status on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance regarding stock listing requirements.
Material Changes
- Delisting Notice: On January 16, 2026, Nasdaq notified the company of a scheduled delisting due to failure to maintain the $1.00 minimum bid price requirement by the January 14, 2026 deadline.
- Reverse Stock Split: Shareholders approved a reverse stock split on January 12, 2026, which was completed on February 20, 2026.
- Listing Status Restored: On March 12, 2026, the Nasdaq Listing Qualifications Hearings Department (Panel) ruled that the company regained compliance with the Minimum Bid Price Requirement following the reverse split.
Outlook, Risks, and Management Commentary
- Compliance Monitoring: The company's common stock will remain listed on Nasdaq but is subject to a one-year monitoring period pursuant to Nasdaq Listing Rule 5815(d)(4)(A).
- Risk Mitigation: The immediate risk of delisting was resolved through the successful appeal and implementation of the reverse stock split.
- Management Action: The company actively appealed the delisting determination on January 21, 2026, and presented a compliance plan to the Panel on February 17, 2026.
Investor Verification Checklist
- Verify the current trading price of ADVB to ensure it remains above the $1.00 threshold during the one-year monitoring period.
- Confirm the exact ratio of the reverse stock split completed on February 20, 2026, to understand the impact on share count and liquidity.
- Review subsequent filings for any new notices from Nasdaq regarding continued compliance.
- Check for any financial disclosures in other recent filings (e.g., 10-Q or 10-K) as this 8-K contains no financial performance data.